New research reveals how a genetic variant found in many centenarians helps the immune system fight chronic inflammation, offering a potential target for future anti-aging therapies.

Researchers have gained new insight into how a rare genetic variant linked to exceptional longevity helps protect the body from age-related disease. The findings explain how the longevity-associated variant of the BPIFB4 gene, commonly found in centenarians, strengthens the immune system by changing the behavior of blood platelets.

Scientists first identified the BPIFB4 variant after discovering it was more common in people who lived to very old ages. Previous studies showed that carriers of the variant experienced lower levels of chronic inflammation, improved cardiovascular health, and a reduced risk of death from age-related conditions.

The latest study sheds light on the biological mechanisms behind these benefits.

Researchers found that the longevity-associated BPIFB4 variant increases the amount of CD47, a protective protein, on the surface of platelets. Although platelets are best known for helping blood clot after injury, they also play an important role in regulating immune responses.

According to the study, platelets with higher CD47 levels are better able to suppress excessive immune activity. In laboratory experiments, these platelets reduced the activation of monocytes, immune cells that contribute to chronic inflammation, and lowered the production of inflammatory signaling molecules.

The research also found that the protective effects were not limited to people who naturally carry the gene variant. When scientists administered a laboratory-produced version of the BPIFB4 protein to mice, platelet CD47 levels increased and inflammatory responses were reduced, producing results similar to those seen in genetic carriers.

These findings suggest that BPIFB4-based therapies could one day reproduce some of the health benefits associated with exceptional longevity, even in people who do not inherit the protective gene variant.

While more research is needed before human treatments become available, the study identifies the BPIFB4–platelet–CD47 pathway as a promising target for future therapies aimed at reducing chronic inflammation, improving immune resilience, and slowing age-related decline.

The discovery adds to growing evidence that healthy aging may be influenced not only by genetics but also by biological pathways that could eventually be targeted with new medicines.